IRIS Accounts Production v23.2.0.158 08030255 Board of Directors 1.5.22 30.4.23 30.4.23 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh080302552022-04-30080302552023-04-30080302552022-05-012023-04-30080302552021-04-30080302552021-05-012022-04-30080302552022-04-3008030255ns10:Originalns15:EnglandWales2022-05-012023-04-3008030255ns14:PoundSterlingns10:Original2022-05-012023-04-3008030255ns10:Originalns10:Director12022-05-012023-04-3008030255ns10:Original2022-05-012023-04-3008030255ns10:Original2023-04-3008030255ns10:Originalns10:PrivateLimitedCompanyLtd2022-05-012023-04-3008030255ns10:Originalns10:SmallEntities2022-05-012023-04-3008030255ns10:Originalns10:AuditExempt-NoAccountantsReport2022-05-012023-04-3008030255ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-05-012023-04-3008030255ns10:SmallCompaniesRegimeForAccountsns10:Original2022-05-012023-04-3008030255ns10:Originalns10:FullAccounts2022-05-012023-04-3008030255ns10:Originalns10:Director22022-05-012023-04-3008030255ns10:Originalns10:RegisteredOffice2022-05-012023-04-3008030255ns10:Original2022-04-3008030255ns10:Originalns5:CurrentFinancialInstruments2023-04-3008030255ns10:Originalns5:CurrentFinancialInstruments2022-04-3008030255ns5:ShareCapitalns10:Original2023-04-3008030255ns5:ShareCapitalns10:Original2022-04-3008030255ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-04-3008030255ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-04-3008030255ns10:Originalns5:PlantMachinery2022-05-012023-04-3008030255ns10:Originalns5:ComputerEquipment2022-05-012023-04-3008030255ns10:Original2021-05-012022-04-3008030255ns10:Originalns5:PlantMachinery2022-04-3008030255ns10:Originalns5:ComputerEquipment2022-04-3008030255ns10:Original2022-04-3008030255ns10:Originalns5:PlantMachinery2023-04-3008030255ns10:Originalns5:ComputerEquipment2023-04-3008030255ns10:Originalns5:PlantMachinery2022-04-3008030255ns10:Originalns5:ComputerEquipment2022-04-3008030255ns10:Originalns5:CostValuation2022-04-3008030255ns10:Originalns5:AdditionsToInvestments2023-04-3008030255ns10:Originalns5:RevaluationsIncreaseDecreaseInInvestments2023-04-3008030255ns10:Originalns5:CostValuation2023-04-3008030255ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-04-3008030255ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-04-30
REGISTERED NUMBER: 08030255 (England and Wales)















Unaudited Financial Statements

for the Year Ended 30 April 2023

for

The Endocrineclinic Ltd

The Endocrineclinic Ltd (Registered number: 08030255)






Contents of the Financial Statements
for the Year Ended 30 April 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


The Endocrineclinic Ltd

Company Information
for the Year Ended 30 April 2023







DIRECTORS: Professor D L Russell-Jones
Mrs S P Russell-Jones





REGISTERED OFFICE: 7 Lindum Terrace
Lincoln
Lincolnshire
LN2 5RP





REGISTERED NUMBER: 08030255 (England and Wales)





ACCOUNTANTS: Stanbridge Associates Limited
7 Lindum Terrace
Lincoln
Lincolnshire
LN2 5RP

The Endocrineclinic Ltd (Registered number: 08030255)

Balance Sheet
30 April 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 793 647
Investments 5 182,105 175,628
182,898 176,275

CURRENT ASSETS
Debtors 6 13,187 27,862
Cash at bank 42,868 11,520
56,055 39,382
CREDITORS
Amounts falling due within one
year

7

56,787

55,787
NET CURRENT LIABILITIES (732 ) (16,405 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

182,166

159,870

CAPITAL AND RESERVES
Called up share capital 105 105
Retained earnings 182,061 159,765
SHAREHOLDERS' FUNDS 182,166 159,870

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The Endocrineclinic Ltd (Registered number: 08030255)

Balance Sheet - continued
30 April 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 6 November 2023 and were signed on its behalf by:





Professor D L Russell-Jones - Director


The Endocrineclinic Ltd (Registered number: 08030255)

Notes to the Financial Statements
for the Year Ended 30 April 2023

1. STATUTORY INFORMATION

The Endocrineclinic Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover represents trading income accrued during the period shown by these financial statements.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 25% Reducing Balance
Computer equipment - 3 Year Straight Line

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2022 - 2 ) .

The Endocrineclinic Ltd (Registered number: 08030255)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2023

4. TANGIBLE FIXED ASSETS
Plant and Computer
machinery equipment Totals
£    £    £   
COST
At 1 May 2022 664 4,733 5,397
Additions - 770 770
At 30 April 2023 664 5,503 6,167
DEPRECIATION
At 1 May 2022 291 4,459 4,750
Charge for year 93 531 624
At 30 April 2023 384 4,990 5,374
NET BOOK VALUE
At 30 April 2023 280 513 793
At 30 April 2022 373 274 647

5. FIXED ASSET INVESTMENTS
Other
investments
£   
COST OR VALUATION
At 1 May 2022 175,628
Additions 15,000
Revaluations (8,523 )
At 30 April 2023 182,105
NET BOOK VALUE
At 30 April 2023 182,105
At 30 April 2022 175,628

The Endocrineclinic Ltd (Registered number: 08030255)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2023

5. FIXED ASSET INVESTMENTS - continued

Cost or valuation at 30 April 2023 is represented by:

Other
investments
£   
Valuation in 2019 71,621
Valuation in 2020 22,194
Valuation in 2021 55,713
Valuation in 2022 26,100
Valuation in 2023 6,477
182,105

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors 13,187 27,862

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade creditors (1 ) 1
Taxation and social security 15,237 14,928
Other creditors 41,551 40,858
56,787 55,787